Combination of DPMAS and Low Volume PE for Patients With HBV Related ACLF
Condition(s) studied
Investigational drug(s) / intervention(s)
Artificial liver support system: Patients will receive treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (PE) for three times, and comprehensive internal medical treatment. The volume of plasma adsorption in DPMAS is 5000\~6000 millilitre. The volume of fresh frozen plasma used in PE is 1000 millilitre.
Study summary
This study is to investigate investigate the safety and efficacy of Double plasma molecular adsorption system with sequential low-dose plasma exchange in treating hepatitis B virus-related acute-on-chronic liver failure.
Eligibility
Primary outcome measure(s)
- Mortality or liver transplantation rate — 12 weeks
Mortality or liver transplantation rate at 12-week follow-up.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Third Affiliated Hospital of Sun Yat-sen University | Guangzhou | Guangdong | Recruiting |
More Third Affiliated Hospital, Sun Yat-Sen University trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04597164 on ClinicalTrials.gov ↗ ← All trials in China